Springpath Expands Into EMEA to Meet Growing Demand for Hyperconvergence
Springpath, the pioneer in hyperconvergence software, today announced its expansion into Europe, the Middle East and Africa (EMEA) with the opening of the regional headquarters in ‘s-Hertogenbosch, the Netherlands and appointment of Johan Pellicaan as Vice President EMEA. The company also announced its first EMEA distribution agreement with Dupaco Distribution in the Netherlands.
Having launched earlier this year in the United States, Springpath’s expansion follows growing demand in the EMEA market for data centre optimisation as enterprises transition to Web-scale, software-defined infrastructure and look to exploit Infrastructure-as-a-Service capabilities.
Springpath offers the industry’s first subscription-based data platform for hyperconvergence that transforms standard servers into a single pool of computing and storage resources that scale elastically. Based on Springpath’s patent pending Hardware Agnostic Log-structured Objects (HALO), the company’s own architecture design, the Springpath Data Platform enables organisations to become more agile through IT infrastructure automation, eliminating storage siloes and reducing the cost of data centre modernisation. With Springpath, enterprises can take data centre infrastructure and converged systems to a new level of performance and efficiency, delivering hyper-efficient utilisation with self-monitoring and self-healing capabilities.
“EMEA is an important market for us. We have ambitious plans to develop our network across the region, expanding our operations and partner base to meet customer demand,” said Johan Pellicaan, Vice President EMEA, Springpath. “EMEA enterprise businesses are looking to address the limitations of their data centre environments in order to compete more innovatively and cost-effectively. Our aim is to help enterprises transform their operations to increase performance and manageability while reducing costs. The Springpath HALO architecture and data platform helps organisations accelerate the transition to Web-scale infrastructure to support the increasing demands of today’s IT workloads and speed of business.”
Recognised as the third wave in infrastructure development, following client/server and virtualisation, hyperconvergence is an important catalyst that is making DevOps a reality for the enterprise. Hyperconvergence software gives organisations the ability to achieve an agile and lean data centre environment for the continuous delivery of modern applications. According to IDC, the hyperconvergence market is expected to grow at 94 percent going into 2016, passing $1.5 billion worldwide.
Commenting on the appointment of Dupaco Distribution as the first EMEA distributor for Springpath, Erik Monninkhof, director and co-founder of Dupaco Distribution, said, “We are excited to add Springpath to our portfolio. The capabilities and functionality in hyperconvergence software will be a true added value for our partners. They are a ground-breaking company bringing a new wave of innovation to the data centre.”
Dupaco Distribution is a leading Value Added Distributor of software in the Dutch ICT market, supporting over 600 enterprise solution partners with pre (sales) process, training and consultancy. Dupaco Distribution provides a mix of open source and Linux / Unix products, as well as specific solutions for Microsoft environments and a portfolio of Saas/Cloud applications.
The Springpath Data Platform is available on a subscription basis for as low as €3.600 per server per year street pricing and supports:
- Servers from Cisco, Dell, Fujitsu, HP, Lenovo and SuperMicro
- Compute platforms like Docker containers, VMware vSphere, Microsoft Hyper-v and OpenStack KVM
- Workloads like Server Virtualization, Development and Test and virtual desktop infrastructure (VDI) including Citrix XenDesktop
To learn more about the Springpath Data Platform, please visit: http://www.springpathinc.com/.
Springpath is the pioneer in hyperconvergence software, turning standard servers of choice into a single pool of compute and storage resources. The Springpath Data Platform eliminates the need for network storage and intuitively integrates into existing management tools to maximize operational efficiency. Using adaptive scaling capabilities, customers can grow compute, caching or capacity resources independently, depending on their changing business needs. Springpath proactively monitors your infrastructure to ensure resilient, always-on availability. Using data management and optimization capabilities, Springpath customers experience transformative levels of resource utilization, accelerating the adoption of DevOps in their organization with truly agile IT infrastructure. For more information, visit www.springpathinc.com or follow us on Twitter @SpringpathInc.
Racepoint Global for Springpath
James Thorniley, +44 (0) 208 811 2124
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom